WO2001094413A3 - B7-related nucleic acids and polypeptides and their uses for immunomodulation - Google Patents

B7-related nucleic acids and polypeptides and their uses for immunomodulation Download PDF

Info

Publication number
WO2001094413A3
WO2001094413A3 PCT/US2001/018257 US0118257W WO0194413A3 WO 2001094413 A3 WO2001094413 A3 WO 2001094413A3 US 0118257 W US0118257 W US 0118257W WO 0194413 A3 WO0194413 A3 WO 0194413A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
nucleic acids
present
immunomodulation
antibodies
Prior art date
Application number
PCT/US2001/018257
Other languages
French (fr)
Other versions
WO2001094413A2 (en
Inventor
Glen E Mikesell
Han Chang
Joshua N Finger
Guchen Yang
Pin Lu
Xia-Di Zhou
Robert Peach
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26904534&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001094413(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to MXPA02012106A priority Critical patent/MXPA02012106A/en
Priority to EP01941978A priority patent/EP1292619B1/en
Priority to JP2002501961A priority patent/JP2004500863A/en
Priority to CA002412377A priority patent/CA2412377A1/en
Priority to AU2001275285A priority patent/AU2001275285A1/en
Priority to DE60132699T priority patent/DE60132699T2/en
Priority to IL15288601A priority patent/IL152886A0/en
Publication of WO2001094413A2 publication Critical patent/WO2001094413A2/en
Publication of WO2001094413A3 publication Critical patent/WO2001094413A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)

Abstract

The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
PCT/US2001/018257 2000-06-06 2001-06-06 B7-related nucleic acids and polypeptides and their uses for immunomodulation WO2001094413A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MXPA02012106A MXPA02012106A (en) 2000-06-06 2001-06-06 B7-related nucleic acids and polypeptides useful for immunomodulation.
EP01941978A EP1292619B1 (en) 2000-06-06 2001-06-06 B7-related nucleic acids and polypeptides and their uses for immunomodulation
JP2002501961A JP2004500863A (en) 2000-06-06 2001-06-06 B7-related nucleic acids and polypeptides useful for immunomodulation
CA002412377A CA2412377A1 (en) 2000-06-06 2001-06-06 B7-related nucleic acids and polypeptides and their uses for immunomodulation
AU2001275285A AU2001275285A1 (en) 2000-06-06 2001-06-06 B7-related nucleic acids and polypeptides and their uses for immunomodulation
DE60132699T DE60132699T2 (en) 2000-06-06 2001-06-06 NUCLEIC ACIDS AND POLYPEPTIDES RELATING TO B7 AND THEIR USES FOR IMMUNOMODULATION
IL15288601A IL152886A0 (en) 2000-06-06 2001-06-06 B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20981100P 2000-06-06 2000-06-06
US60/209,811 2000-06-06
US27210701P 2001-02-28 2001-02-28
US60/272,107 2001-02-28

Publications (2)

Publication Number Publication Date
WO2001094413A2 WO2001094413A2 (en) 2001-12-13
WO2001094413A3 true WO2001094413A3 (en) 2002-07-25

Family

ID=26904534

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/018257 WO2001094413A2 (en) 2000-06-06 2001-06-06 B7-related nucleic acids and polypeptides and their uses for immunomodulation

Country Status (11)

Country Link
US (9) US6965018B2 (en)
EP (1) EP1292619B1 (en)
JP (1) JP2004500863A (en)
AT (1) ATE385504T1 (en)
AU (1) AU2001275285A1 (en)
CA (1) CA2412377A1 (en)
DE (1) DE60132699T2 (en)
ES (1) ES2300340T3 (en)
IL (1) IL152886A0 (en)
MX (1) MXPA02012106A (en)
WO (1) WO2001094413A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9370565B2 (en) 2000-04-28 2016-06-21 The Johns Hopkins University Dendritic cell co-stimulatory molecules
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411051B2 (en) * 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
DK1234031T3 (en) * 1999-11-30 2017-07-03 Mayo Foundation B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
US6965018B2 (en) * 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
US20030031675A1 (en) * 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
CA2413857C (en) * 2000-06-28 2010-04-27 Genetics Institute, Llc. Pd-l2 molecules: pd-1 ligands and uses therefor
US6635750B1 (en) 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
AU2001286205A1 (en) * 2000-09-12 2002-03-26 Kirin Beer Kabushiki Kaisha Novel dendritic cell wall membrane and use thereof
JP4584536B2 (en) * 2000-09-20 2010-11-24 アムジェン インコーポレイテッド B7-like molecules and uses thereof
WO2002086083A2 (en) * 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
EP1423402A4 (en) * 2001-08-02 2006-07-05 Lilly Co Eli Novel polypeptide analogs and fusions and their methods of use
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
DK1565489T3 (en) 2002-06-19 2011-03-07 Raven Biotechnologies Inc Internalizing antibodies specific for the RAAG10 cell surface target
EP1539228B1 (en) 2002-09-11 2010-12-29 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
US20040248205A1 (en) * 2003-04-16 2004-12-09 Stern Lawrence J. Major histocompatibility complex (MHC)-peptide arrays
US20050002935A1 (en) * 2003-04-17 2005-01-06 Vincent Ling Use of B7-H3 as an immunoregulatory agent
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
JP5130044B2 (en) * 2004-08-03 2013-01-30 イナート・ファルマ Therapeutic and diagnostic methods and compositions targeting 4IG-B7-H3 and its corresponding NK cell receptor
MX2007004176A (en) 2004-10-06 2007-06-15 Mayo Foundation B7-h1 and methods of diagnosis, prognosis, and treatment of cancer.
ES2772674T3 (en) 2005-05-12 2020-07-08 Zymogenetics Inc Compositions and methods for modulating immune responses
KR101600225B1 (en) 2005-06-08 2016-03-04 다나-파버 캔서 인스티튜트 인크. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
MX2007015942A (en) 2005-07-01 2008-03-07 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (pd-l1).
BRPI0620601A2 (en) * 2005-12-08 2011-11-16 Medarex Inc isolated human monoclonal antibody or antigen-binding portion thereof, composition, immunoconjugate, isolated nucleic acid molecule, expression vector, host cell, method for preparing an anti-o8e antibody and method for treating or preventing a disease defined by the growth of o8e expressing tumor cells
WO2007082144A2 (en) * 2006-01-05 2007-07-19 Mayo Foundation For Medical Education And Research B7-h1 and survivin in cancer
WO2007082154A2 (en) * 2006-01-05 2007-07-19 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
WO2008066691A2 (en) * 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
WO2008083174A2 (en) * 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
EP2170946A2 (en) 2007-07-13 2010-04-07 The Johns Hopkins University B7-dc variants
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
CN106349390B (en) 2008-04-02 2019-12-10 宏观基因有限公司 BCR-complex-specific antibodies and methods of use thereof
CA3179151A1 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
AU2009288289B2 (en) * 2008-08-25 2012-11-08 Amplimmune, Inc. PD-1 antagonists and methods of use thereof
CA2734908A1 (en) * 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
CN102282265B (en) * 2008-11-28 2020-07-24 埃默里大学 Methods for treating infectious diseases and tumors
TWI686405B (en) 2008-12-09 2020-03-01 建南德克公司 Anti-pd-l1 antibodies and their use to enhance t-cell function
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
PL3903829T3 (en) 2009-02-13 2023-08-14 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
AU2010282340B2 (en) 2009-08-13 2016-12-22 The Johns Hopkins University Methods of modulating immune function
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
EP2504028A4 (en) * 2009-11-24 2014-04-09 Amplimmune Inc Simultaneous inhibition of pd-l1/pd-l2
EP2506881B1 (en) 2009-12-02 2024-03-06 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
EP2625263B1 (en) 2010-10-08 2020-03-11 Terumo BCT, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
BR112015013444B1 (en) 2012-12-13 2022-11-01 Immunomedics, Inc USE OF AN IMMUNOCONJUGATE
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
AU2014290069B2 (en) 2013-07-16 2019-01-03 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
EP3052131B1 (en) 2013-10-01 2018-12-05 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
TR201802728T4 (en) 2013-10-25 2018-03-21 Psioxus Therapeutics Ltd Oncolytic adenoviruses equipped with heterologous genes.
JP6633522B2 (en) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド Cell growth in bioreactors
CA2935804A1 (en) * 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
JP6533534B2 (en) 2014-02-14 2019-06-19 マクロジェニクス，インコーポレーテッド Composition for use in the treatment of glioblastoma and use thereof
AU2015219495B2 (en) 2014-02-21 2019-11-21 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
EP3110445A4 (en) 2014-02-25 2017-09-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
EP3171896A4 (en) 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Targeting dna-pkcs and b7-h1 to treat cancer
WO2016040892A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies
JP6830059B2 (en) 2014-09-26 2021-02-17 テルモ ビーシーティー、インコーポレーテッド Scheduled cell feeding
CN114920840A (en) 2014-10-14 2022-08-19 诺华股份有限公司 Antibody molecules against PD-L1 and uses thereof
JP6746845B2 (en) 2015-04-22 2020-08-26 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． Isolation, detection, diagnosis and/or characterization of circulating TROP-2 positive cancer cells
JP6905941B2 (en) * 2015-06-23 2021-07-21 バイエル ファーマ アクチエンゲゼルシャフト Antibody drug conjugate with anti-B7H3 antibody of kinesin spindle protein (KSP) inhibitor
JP2018524313A (en) * 2015-06-23 2018-08-30 バイエル ファーマ アクチエンゲゼルシャフト Antibody-drug complex of kinesin spindle protein (KSP) inhibitor with anti-B7H3 antibody
EP3313443B9 (en) 2015-06-25 2023-10-04 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
JP6764474B2 (en) 2015-09-25 2020-09-30 ジェネンテック， インコーポレイテッド Anti-TIGIT antibody and usage
CN108136010A (en) 2015-10-08 2018-06-08 宏观基因有限公司 For the conjoint therapy for the treatment of cancer
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
AU2016348391A1 (en) 2015-11-03 2018-05-17 Janssen Biotech, Inc. Antibodies specifically binding TIM-3 and their uses
BR112018012180A2 (en) 2015-12-17 2018-12-04 Psioxus Therapeutics Ltd virus encoding an anti-tcr antibody or fragment
US10961311B2 (en) 2016-04-15 2021-03-30 Macrogenics, Inc. B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN117247899A (en) 2017-03-31 2023-12-19 泰尔茂比司特公司 cell expansion
MX2020010913A (en) 2018-04-17 2021-01-08 Celldex Therapeutics Inc Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs.
WO2022239720A1 (en) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 Antibody having reduced binding affinity for antigen

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019706A1 (en) * 1996-11-08 1998-05-14 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
WO1999047558A2 (en) * 1998-03-19 1999-09-23 Heska Corporation T cell costimulatory proteins, sequences and uses thereof
WO2001014556A1 (en) * 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Novel b7-4 molecules and uses therefor

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185432A (en) 1986-02-26 1993-02-09 Oncogen Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
WO1992000092A1 (en) 1990-07-02 1992-01-09 Bristol-Myers Squibb Company Ligand for cd28 receptor on b cells and methods
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
US7411051B2 (en) * 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
WO2001018022A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins
US7368531B2 (en) * 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
WO1998058965A2 (en) 1997-06-20 1998-12-30 Innogenetics N.V. B7-binding molecules for treating immune diseases
ES2312205T3 (en) 1998-03-10 2009-02-16 Genentech, Inc. NEW POLYPEPTIDE AND NUCLEIC ACIDS THAT CODE IT.
WO2000008057A2 (en) 1998-08-07 2000-02-17 Immunex Corporation Molecules designated b7l-1
CA2361840A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU3899700A (en) 1999-03-17 2000-10-04 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
HUP0200760A2 (en) 1999-04-02 2002-06-29 Corixa Corp Compounds and methods for therapy and diagnosis of lung cancer
AU4640600A (en) 1999-05-11 2000-11-21 Eli Lilly And Company Amyloid precursor protein protease and related nucleic acid compounds
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
EP1396543A3 (en) 1999-07-08 2004-03-31 Research Association for Biotechnology Primers for synthesizing full length cDNA clones and their use
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
ATE431416T1 (en) 1999-08-20 2009-05-15 Pasteur Institut ENZYMATIC SYNTHESIS OF DEOXYRIBONUCLEOTIDES
CA2383456C (en) 1999-08-23 2016-06-07 Clive Wood Pd-1, a receptor for b7-4, and uses therefor
WO2001014577A1 (en) 1999-08-24 2001-03-01 Smithkline Beecham Corporation Molecular cloning of a galanin like 7tm receptor (axor40)
JP2003512819A (en) 1999-09-03 2003-04-08 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド B7-like polynucleotides, polypeptides and antibodies
US6429303B1 (en) * 1999-09-03 2002-08-06 Curagen Corporation Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
WO2001021631A2 (en) 1999-09-20 2001-03-29 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
AU7810900A (en) 1999-10-21 2001-04-30 Nokia Corporation Mobile station execution of packet control channel (pcch) transition during broadcast control channel (bcch) update
AU1448701A (en) 1999-11-09 2001-06-06 Human Genome Sciences, Inc. 15 human secreted proteins
AU1473501A (en) 1999-11-12 2001-06-06 Human Genome Sciences, Inc. 21 human secreted proteins
DK1234031T3 (en) 1999-11-30 2017-07-03 Mayo Foundation B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
WO2001053312A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US6965018B2 (en) * 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
CA2413857C (en) 2000-06-28 2010-04-27 Genetics Institute, Llc. Pd-l2 molecules: pd-1 ligands and uses therefor
WO2002002587A1 (en) 2000-06-30 2002-01-10 Human Genome Sciences, Inc. B7-like polynucleotides, polypeptides, and antibodies
US6635750B1 (en) * 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
US6891030B2 (en) * 2000-07-27 2005-05-10 Mayo Foundation For Medical Education And Research T-cell immunoregulatory molecule
AU2001286205A1 (en) 2000-09-12 2002-03-26 Kirin Beer Kabushiki Kaisha Novel dendritic cell wall membrane and use thereof
EP1322614A2 (en) 2000-09-18 2003-07-02 E. I. du Pont de Nemours and Company Pyridinyl amides and imides for use as fungicides
JP4584536B2 (en) * 2000-09-20 2010-11-24 アムジェン インコーポレイテッド B7-like molecules and uses thereof
EP1401999A4 (en) 2001-05-25 2005-09-14 Amgen Inc B7 related protein-2 molecules and uses thereof
EP1423402A4 (en) 2001-08-02 2006-07-05 Lilly Co Eli Novel polypeptide analogs and fusions and their methods of use
US20040162236A1 (en) * 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
KR100575710B1 (en) 2002-07-20 2006-05-03 엘지전자 주식회사 Uplink syncronization detection method
US20050002935A1 (en) 2003-04-17 2005-01-06 Vincent Ling Use of B7-H3 as an immunoregulatory agent
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
US8803367B2 (en) 2008-12-22 2014-08-12 Telefonaktiebolaget L M Ericsson (Publ) Sub sampling electrical power conversion
WO2011030094A2 (en) 2009-09-09 2011-03-17 Syngenta Limited Fungicidal mixtures
EP3474219A4 (en) 2016-06-28 2019-07-03 Konica Minolta, Inc. Nursing/care item input device, nursing/care item input method, and nursing/care item management system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019706A1 (en) * 1996-11-08 1998-05-14 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
WO1999047558A2 (en) * 1998-03-19 1999-09-23 Heska Corporation T cell costimulatory proteins, sequences and uses thereof
WO2001014556A1 (en) * 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Novel b7-4 molecules and uses therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DONG H ET AL: "B7-H1, A THIRD MEMBER OF THE B7 FAMILY, CO-STIMULATES T-CELL PROLIFERATION AND INTERLEUKIN-10 SECRETION", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 5, no. 12, December 1999 (1999-12-01), pages 1635 - 1639, XP000971288, ISSN: 1078-8956 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370565B2 (en) 2000-04-28 2016-06-21 The Johns Hopkins University Dendritic cell co-stimulatory molecules
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof

Also Published As

Publication number Publication date
US20140194598A1 (en) 2014-07-10
DE60132699T2 (en) 2009-01-29
IL152886A0 (en) 2003-06-24
US20020095024A1 (en) 2002-07-18
AU2001275285A1 (en) 2001-12-17
MXPA02012106A (en) 2003-06-06
US20090215995A1 (en) 2009-08-27
US7358354B2 (en) 2008-04-15
US20160340408A1 (en) 2016-11-24
EP1292619A2 (en) 2003-03-19
US20100136575A1 (en) 2010-06-03
CA2412377A1 (en) 2001-12-13
US20060140937A1 (en) 2006-06-29
US9409970B2 (en) 2016-08-09
US20120329990A1 (en) 2012-12-27
ES2300340T3 (en) 2008-06-16
DE60132699D1 (en) 2008-03-20
US8080636B2 (en) 2011-12-20
US7723479B2 (en) 2010-05-25
US8664360B2 (en) 2014-03-04
US20050208525A1 (en) 2005-09-22
JP2004500863A (en) 2004-01-15
US7279567B2 (en) 2007-10-09
US6965018B2 (en) 2005-11-15
EP1292619B1 (en) 2008-02-06
ATE385504T1 (en) 2008-02-15
US20200079835A1 (en) 2020-03-12
WO2001094413A2 (en) 2001-12-13
US10400023B2 (en) 2019-09-03

Similar Documents

Publication Publication Date Title
WO2001094413A3 (en) B7-related nucleic acids and polypeptides and their uses for immunomodulation
WO2002099119A3 (en) B7-related nucleic acids and polypeptides useful for immunomodulation
EP1304382A3 (en) Production of peptides in plants as viral coat protein fusions
WO2002061071A3 (en) Focused libraries of genetic packages
WO2001073059A3 (en) 38692 and 21117: dual specificity phosphatase molecules and uses therefor
WO1999003881A3 (en) Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
WO2002036627A3 (en) Interferons, uses and compositions related thereto
EP1892251A3 (en) B7-related nucleic acids and polypeptides and their uses for immunomodulation
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
WO2000059942A3 (en) Human obesity protein binding protrein-2 homolog and uses thereof
WO2002068591A3 (en) G-protein coupled receptor nucleic acids, polypeptides, antibodies and uses thereof
WO2002002771A3 (en) Human sparc-homologous (hsparc-h1) gene and methods and uses thereof
WO2001083719A3 (en) 25692, a novel human o-methyltransferase family member and uses thereof
WO2001083552A3 (en) Human sez6 nucleic acids and polypeptides
WO2001036476A3 (en) Ing2, an iaps associated cell cycle protein, compositions and methods of use
WO2001096400A3 (en) 52871, a novel human g protein coupled receptor and uses thereof
WO2002010391A3 (en) 18610, a human transient receptor and uses thereof
WO2001077329A8 (en) Human twik molecules and uses thereof
WO2001042295A3 (en) Clasp-7 transmembrane protein
WO2001040461A3 (en) Cdna sequence of two interactors fancip4 and fancip5 of the fanconi anaemia proteins of the complementation groups a and c
WO2002029041A3 (en) 32146 and 57259, novel human transporters and uses thereof
WO2002006326A3 (en) 62088, a human nucleoside phosphatase family member and uses thereof
WO2002026983A3 (en) 56115, a novel human twik potassium channel and uses therefor
WO2002024911A3 (en) 63760, a novel human transporter and uses thereof
WO2001085908A9 (en) Clasp-1 transmembrane protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA IL JP MX

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 152886

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2412377

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001275285

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 501961

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/012106

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2001941978

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001941978

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001941978

Country of ref document: EP